BioXcel Therapeutics Q4 net loss $10.9M; SERENITY Phase 3 trial 63% enrolled; cash ~$35M

BioXcel Therapeutics, Inc.

Net loss $10.9M in Q4 2024 vs $22.3M Q4 2023; full-year net loss $59.6M vs $179.1M.
IGALMI net revenue $366K in Q4 ($376K Q4 2023); full-year $2.3M vs $1.4M in 2023.
SERENITY At-Home Phase 3 trial enrollment at 63% (127/200 patients); topline data expected H2 2025.
Closed $14M equity financing, strengthening cash to ~$35M as of March 4, 2025 (from $29.9M Dec 31, 2024).
Cash used in operating activities $72M in 2024, down from $155M in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.